{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"19.3","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"}],"units":"Participants"}],"title":"HRD positive, n=221"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"5.9","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"}],"units":"Participants"}],"title":"HRD negative, n=195"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"18.3","value":"6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"HRD unknown, n=45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.6","upperLimit":"33.2","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"BRCA mutation positive, n=87"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"8.1","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"}],"units":"Participants"}],"title":"BRCA wild-type, n=317"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"14.6","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"BRCA unknown, n=57"}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"}],"units":"Participants"}],"description":"The ORR was defined as the percentage of participants achieving CR or PR as assessed by the Investigator per RECIST (version1.1), where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. ORR was evaluated for participants with following characteristics: HRD status (positive, negative and unknown) and BRCA status (mutation positive, wild-type and unknown).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"paramType":"NUMBER","populationDescription":"ITT Population. All the participants from the ITT Population were analyzed (461 participants), but only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"ORR by HRD Status and Breast Cancer Gene (BRCA) Status","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}